Metabolomics Technology Applied to Non-Invasive Nash Biomarkers Research
News May 17, 2010
Metabolon, Inc. announces a study published in the Metabolism Journal released in the paper on April 28, 2010, by Satish C. Kalhan.
Metabolon studied plasma profiles from subjects with nonalcoholic fatty liver disease (NAFLD). Using Metabolon’s patented global metabolomic profiling platform, the study, authored by Satish C. Kalhan and his collaborators at the Cleveland Clinic and Case Western Reserve University School of Medicine and with scientists from Metabolon, identified a panel of potential noninvasive biomarkers in NAFLD and Nonalcoholic Steatohepatitis (NASH). The results represent both a significant step in understanding the disease and for the development of therapeutic interventions.
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
A Mystery Solved: "Protein Cluedo" Reveals Enzyme SecretsNews
Scientists have used biosensors to solve questions about protein production which might seem familiar to mystery board game enthusiasts.READ MORE
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE
Comments | 1 ADD COMMENT
Ana Aitawa | Oct 03, 2017
The global nonalcoholic steatohepatitis (NASH) treatment market is estimated to reach US$ 19.8 Billion in 2025, expanding at a CAGR of 10.0% from 2017 to 2025, mainly driven by expected approval of Aramchol, Elafibranor, Obeticholic acid, and Simtuzumab, and introduction of several new high-priced products. Moreover, combination therapies are likely to dominate the global market over the forecast period. Visit Nonalcoholic Steatohepatitis Treatment Market by Drug Type (Pioglitazone and Type 2 Diabetes Mellitus (T2DM) Medicines, Vitamin E, Others), Pipeline Analysis (Phase III Drugs - Aramchol (Arachidyl Amido Cholanoic Acid), Elafibranor (GFT505), Emricasan (IDN-6556, PF-03491390), Obeticholic Acid (OCA/Ocaliva), Simtuzumab (GS-6624), Others), and Phase I and II Drugs 2017-2025 at https://www.ihealthcareanalyst.com/global-nonalcoholic-steatohepatitis-treatment-market/